Efficacy and Safety of Rosuvastatin 5 mg in Combination with Fenofibric Acid 135 mg in Patients with Mixed Dyslipidemia – A Phase 3 Study

Efficacy and Safety of Rosuvastatin 5 mg in Combination with Fenofibric Acid 135 mg in Patients with Mixed Dyslipidemia – A Phase 3 Study

Background Patients with mixed dyslipidemia characterized by elevated low-density lipoprotein cholesterol (LDL-C), elevated triglycerides (TG), and reduced high-density lipoprotein cholesterol (HDL-C) often require combination therapy to improve multiple lipid and nonlipid parameters. This phase 3,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cardiovascular drugs and therapy 2010-12, Vol.24 (5-6), p.421-428
Hauptverfasser: Roth, Eli M., Rosenson, Robert S., Carlson, Dawn M., Fukumoto, Sandra M., Setze, Carolyn M., Blasetto, James W., Khurmi, Nardev S., Stolzenbach, James C., Williams, Laura A.
Format: Artikel
Sprache:eng
Schlagworte:
Aged
Anticholesteremic Agents - administration & dosage
Anticholesteremic Agents - adverse effects
Biological and medical sciences
Cardiology
Cardiovascular system
Cholesterol, HDL - metabolism
Cholesterol, LDL - metabolism
Double-Blind Method
Drug Therapy, Combination
Dyslipidemias - drug therapy
Dyslipidemias - metabolism
Female
Fenofibrate - administration & dosage
Fenofibrate - adverse effects
Fenofibrate - analogs & derivatives
Fluorobenzenes - administration & dosage
Fluorobenzenes - adverse effects
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
Male
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Pharmacology. Drug treatments
Pyrimidines - administration & dosage
Pyrimidines - adverse effects
Rosuvastatin Calcium
Sulfonamides - administration & dosage
Sulfonamides - adverse effects
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Patients with mixed dyslipidemia characterized by elevated low-density lipoprotein cholesterol (LDL-C), elevated triglycerides (TG), and reduced high-density lipoprotein cholesterol (HDL-C) often require combination therapy to improve multiple lipid and nonlipid parameters. This phase 3, multicenter, randomized, double-blind study evaluated the efficacy and safety of rosuvastatin 5 mg coadministered with fenofibric acid 135 mg in patients with mixed dyslipidemia. Methods A total of 760 patients with TG ≥ 150 mg/dL, HDL-C
ISSN:0920-3206
1573-7241
DOI:10.1007/s10557-010-6266-4